Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label study of MK-6070 with ifinatamab deruxtecan, MK-6070 alone, or MK-6070 with durvalumab in relapsed/refractory extensive-stage small cell lung cancer
CTR20253994Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gocatamig, ifinatamab deruxtecan, durvalumab in small cell lung cancer (SCLC), sponsored by Merck & Co.. Started Dec 2025; status: active.
02
Drugs
gocatamigifinatamab deruxtecandurvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20253994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253994.